Table 2.
Receipt of neoadjuvant chemotherapy and endocrine therapy by clinical stage.
| Stage | Neoadjuvant endocrine therapy only N (%) |
Neoadjuvant chemotherapy* N (%) |
No neoadjuvant systemic therapy N (%) |
P-value |
|---|---|---|---|---|
| IIA (T2N0 only) | 594 (1) | 10,126 (17) | 48,061 (82) | <.0001 |
| IIB (T2N1, T3N0) | 299 (1) | 13,656 (45) | 16,681 (54) | |
| IIIA (T3N1 only) | 75 (1) | 5,865 (74) | 2,009 (25) | |
| IIIA (T0-3N2 only) | 50 (1) | 3,546 (44) | 4,428 (55) | <.0001 |
| IIIB non-inflammatory (T4N0-2) | 81 (2) | 3,871 (79) | 932 (19) | |
| IIIC non-inflammatory (N3) | 27 (1) | 2,231 (53) | 1,963 (47) | |
| Inflammatory (T4d) | 5 (<1) | 3,353 (93) | 233 (7) |
*
With or without neoadjuvant endocrine therapy